Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8491 to 8505 of 8906 results

  1. COVID-19 rapid guideline: severe asthma (NG166)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.

  2. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  3. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.

  4. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  5. COVID-19 rapid guideline: acute myocardial injury (NG171)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  6. COVID-19 rapid guideline: cystic fibrosis (NG170)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with cystic fibrosis see our guideline on diagnosing and managing cystic fibrosis and for people with COVID-19 see our guideline on managing COVID-19.

  7. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  8. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For children and young people with COVID-19 see our guideline on managing COVID-19

  9. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  10. COVID-19 rapid guideline: chronic kidney disease (NG176)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with chronic kidney disease see our guideline on assessing and managing chronic kidney disease and for people with COVID-19 see our guideline on managing COVID-19.

  11. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  12. COVID-19 rapid guideline: interstitial lung disease (NG177)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.